ReviewSurgery today2026
Long-term outcomes of bridge to surgery using colonic stents and emergency surgery in right-sided obstructive colon cancer: A systematic review and meta-analysis.
Review in Surgery today, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This systematic review and meta-analysis evaluated the long-term oncological outcomes of colonic stenting as a bridge to surgery (BTS) compared with emergency surgery (ES) in patients with right-sided obstructive colon cancer (OCC). A systematic literature search of the MEDLINE, Cochrane Central Register of Controlled Trials, and ICHUSHI-Web databases up to January 2026 identified studies comparing disease-free survival (DFS) and/or overall survival (OS) between BTS and ES. A meta-analysis was conducted using random-effects model. Five retrospective studies comprising 609 patients (BTS, n = 207; ES, n = 402) were included, with three studies from China and two from South Korea. The pooled analysis showed no significant difference in DFS between BTS and ES (hazard ratio [HR]: 0.86; 95% confidence interval [CI]: 0.65-1.14; P = 0.30), without heterogeneity (χ² = 0.38; I² = 0%; P = 0.94). Similarly, OS was comparable between the two groups (HR: 0.99; 95% CI: 0.76-1.29; P = 0.93), without heterogeneity (χ² = 2.82; I² = 0%; P = 0.59). Although no significant differences in the long-term oncological outcomes were observed between BTS and ES, these findings should be interpreted with caution because the available evidence remains limited. Further prospective studies are warranted to clarify the long-term oncological impact of BTS in patients with right-sided OCC.
Indexed as
Identifiers
42726123What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.